Skip to main content

Table 1 Baseline characteristics by BMI for patients treated with PD-1 blockade

From: Complex inter-relationship of body mass index, gender and serum creatinine on survival: exploring the obesity paradox in melanoma patients treated with checkpoint inhibition

N = 139 Body Mass Index (kg/m2)
BMI < 25 kg/m2 N = 38a(%) Overweight and Class I Obesity (BMI 25- < 35 kg/m2) N = 86 (%) Class II/III Obesity (BMI ≥ 35 kg/m2) N = 15 (%)
Demographics
 Age 64.6 (15.2) 61.2 (13.8) 57.3 (13.7)
 Male gender 19 (50) 57 (66.3) 3 (20)
 White race 37 (97.4) 85 (98.8) 14 (93.3)
 Cutaneous Melanoma 31 (81.6) 78 (90.7) 12 (80)
 BRAF V600 mutation 11 (28.9) 22 (25.6) 2 (13.3)
 NRAS mutation 4 (10.5) 6 (7) 4 (26.7)
Disease severity
 Stage at baseline IV M1c: 24 (63.2) IV M1c: 49 (57) IV M1c: 7 (46.7)
 Karnofsky Performance Score (KPS) < 70: 2 (5.3)
> = 70: 36 (94.7)
< 70: 2 (2.4)
> = 70: 83 (97.6)
N = 85/86
< 70: 0 (0)
> = 70: 15 (100)
 LDH in U/L (Median and IQR; N = 131) 211.5 (158–336)
N = 34/38
176.5 (137–230)
(N = 82/86)
187 (158–264)
Lifestyle habits
 Ever smokers Former: 16 (42.1)
Current: 3 (7.9)
Former: 34 (39.5)
Current: 8 (9.3)
Former: 7 (46.7)
Current: 0 (0)
 Current drinkers 24 (63.2) 54 (62.8) 6 (40)
Prior treatments
 Immunotherapy 9 (23.7) 33 (38.4) 8 (53.3)
 Chemotherapy 1 (2.6) 12 (14) 2 (13.3)
 Radiation 10 (26.3) 22 (25.6) 6 (40)
 Targeted therapy 5 (13.2) 5 (5.8) 0 (0)
Co-morbidities
 Charlson’s Comorbidity Index (Mean and SD) 8.6 (1.7) 8.4 (2.1) 8.1 (1.7)
 Diabetes 3 (7.9) 11 (12.8) 4 (26.7)
 Hypertension 14 (36.8) 51 (59.3) 9 (60)
 Hyperlipidemia 11 (28.9) 27 (31.4) 8 (53.3)
 Chronic Kidney Disease (CKD) 3 (7.9) 7 (8.1) 1 (6.7)
 Cardiovascular disease (CAD/CHF/MI/AF)c 6 (15.8) 11 (12.8) 4 (26.7)
 Autoimmune/Immune mediated disorders 7 (18.4) 9 (10.5) 1 (6.7)
Co-medications for co-morbidities
 Anti-platelet agents (Aspirin/Clopidogrel) 10 (26.3) 22 (25.6) 4 (26.7)
 Anti-hypertensive medications (any) 10 (26.3) 49 (57) 9 (60)
 ACE or ARB inhibitors 7 (18.4) 28 (32.6) 4 (2.7)
 Metformin 3 (7.9) 6 (7) 3 (20)
 Statins 11 (2.9) 20 (23.3) 4 (26.7)
 Oral Steroids 1 (2.6) 10 (11.6) 1 (6.7)
Clinical chemistry and Vitals
 Albumin in g/dL (Mean and SD) 3.8 (0.59) 4.1 (0.41) 4 (0.45)
 ANC K/uL (Mean and SD) 5.5 (3.3) 4.8 (1.6) 5.5 (2.7)
 ALC K/uL (Mean and SD) 1.3 (0.6) 1.6 (1.4) 1.8 (1.1)
 Hemoglobin g/dL (Mean and SD) 12.4 (2) 13.1 (1.6) 12.2 (1.5)
 Serum Creatinine mg/dL (Mean and SD) 0.81 (0.21) 0.95 (0.38) 0.88 (0.36)
 eGFRb (ml/min/1.73m2) > = 60: 36; < 60: 2 > = 60: 77; < 60: 9 > = 60: 13; < 60: 2
 eGFR by CKD-EPI equation in ml/min/1.73m2 (Median and IQR) 88.51 (71.09–98.91) 85.87 (74.83–94.73) 91.03 (70.99–100.6)
 Fasting Glucose in mg/dL (Median and IQR) 106 (100–122) 101 (93–119) 102 (98–114)
 BMI at baseline (kg/m2) 22.6 (2.3) 29.1 (2.7) 40.1 (4.4)
 Alkaline Phosphatase in U/L (Median and IQR) 74 (63–100) 74 (62–90) 69 (60–129)
 ALT in U/L (Median and IQR) 15 (11–27) 17 (12–21) 18 (14–27)
 AST in U/L (Median and IQR) 19 (15–29) 18 (13–23) 21 (13–27)
 Systolic blood pressure in mm Hg (Mean/SD) 124.7 (19.9) 133.8 (18.2) 135.3 (14.4)
 Diastolic blood pressure in mm Hg (Mean/SD) 74.4 (11.9) 78.3 (13.2) 75 (10.6)
Disease related weight loss
 BMI measured up to 6 months before baseline (Mean and SD) 23 (2.6) (N = 35/38) 29.3 (2.7) (N = 81/86) 40.4 (4.8)
Treatment
 Anti-PD-1 immunotherapy type Mono: 19 (50)
Combination:19 (50)
Mono: 49 (57)
Combination: 37 (43)
Mono: 11 (73.3)
Combination: 4 (26.7)
  1. aIncludes three patients with BMI < 18.5 for descriptive purposes. Analyses by Cox-PH/logistic regression was performed by excluding underweight patients (n = 3) but were included for RSF analysis where BMI was included as a continuous variable
  2. beGFR Estimated Glomerular Filtration Rate (Cockcroft-Gault)
  3. cCAD Coronary Artery Disease, CHF Congestive Heart Failure, MI Myocardial Infarction and AF Atrial Fibrillation
  4. IQR Inter Quartile Range